@ARTICLE{
author={Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Mercadal Santiago,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,Genevray Magali,Zharkov Artem,Dixon Mark,Brewster Michael,Barrett Martin,MacDonald David},
year={2017},
title={Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial},
journal={LANCET HAEMATOLOGY},
volume={4},
number={6},
pages={E272-E282},
document_type={Article},
} 

@ARTICLE{
author={Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Phillippe,Barrett Martin,Berge Claude,Bittner Beate,Boehnke Axel,McIntyre Christine,MacDonald David},
year={2014},
title={Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study},
journal={LANCET ONCOLOGY},
volume={15},
number={3},
pages={343-352},
document_type={Article},
}